Dr. Reddy's rises on India distribution deal for Takeda's dengue vaccine

Takeda Pharmaceutical

18/09/2026 05:45

** Shares of India's Dr. Reddy's REDY.NS rise as much as 2.76% to 1,207.50 rupees
** REDY's signed an agreement with Japanese drugmaker Takeda Pharmaceutical 4502.T to promote and distribute the Qdenga dengue vaccine in India
** India's drug regulator approved Qdenga for use in both children and adults, making it the first dengue vaccine cleared for the country
** Dr Reddy's said Qdenga, a two-dose dengue vaccine administered three months apart without the need for pre-vaccination screening, is expected to be available in India in the first half of 2027
** Thirty-six analysts have a "Hold" rating on avg; median PT is 1,221 rupees - data compiled by LSEG
** YTD, REDY down 4.2%

(Reporting by Urvi Dugar in Bengaluru)
((UrviManoj.Dugar@thomsonreuters.com; +91 9558725583; ))